Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns Exact Sciences of Noncompliance with $50M Market Cap Minimum

NEW YORK (GenomeWeb News) – Exact Sciences has received notice from the Nasdaq Stock Market that it is not in compliance with the Nasdaq Global Market’s listing’s requirement of a minimum $40 million market capitalization, the company said today.
 
Exact Sciences’ market cap is currently $36.4 million.
 
The company has 30 calendar days, or until Aug. 11, to regain compliance by maintaining a minimum $50 million market value for at least 10 consecutive business days.
 
If the company has not regained compliance by that time, it will face delisting proceedings, which it can appeal. Alternatively, it may apply to transfer its shares to the Nasdaq Capital Market, which requires a minimum market capitalization of $35 million.
 
Exact said in a statement that it “believes that it meets the continued inclusion requirements for listing on the Nasdaq Capital Market.”
 
Exact announced yesterday that it is beginning clinical studies for its DNA-based colorectal cancer screening test and that it plans to file for 510(k) approval for the test with the US Food and Drug Administration by the third quarter of 2009.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.